Scientific Publications
This page contains a partial list of Access Pharmaceuticals' publications, presented either in scientific journals or at major scientific conferences. Due to copyright restrictions, we cannot provide copies of journal articles, but links are provided to the Pubmed abstract of the article. Poster presentations are available for download. Click on the link to the right of the publication to view either the abstract or the poster.
ProLindacTM (AP5346)
| M Campone, AM Floquet, F Rousseau, et al, (2007) AP5436, a pH-dependent polymer vectorized DACH, is safe at pharmacodynamically active doses: results from an ongoing Phase II trial in potentially platinum-sensitive ovarian cancer (OC) patients, Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on November 22-26 2007 in San Francisco, CA | Poster |
| M Serova, N Aissat, A Ghoul, et al, (2007) Molecular and cellular effects of AP5346, a novel DACH-platinum linked polymer compound, compared to oxaliplatin and cisplatin in a panel of human cancer cell lines, Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on November 22-26 2007 in San Francisco, CA | Poster |
| N Aissat, M Serova, A Ghoul, et al, (2007) Antiproliferative activity of AP5346, a novel DACH-platinum compound, alone and in combination with other cytotoxics, in human colon and ovarian cancer cells, Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on November 22-26 2007 in San Francisco, CA | Poster |
| P Sood, KB Thurmond, JE Jacob, et al, (2006) Synthesis and Characterization of AP5346, a Novel Polymer-Linked Diaminocyclohexyl Platinum Chemotherapeutic Agent, Bioconjugate Chem., 17, 1270-1279 | Abstract |
| JR Rice, JL Gerberich, DP Nowotnik, SB Howell (2006) Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-PlatinumTumor-Targeting Drug Delivery System, Clin. Cancer Res.,12, 2248-2254 | Abstract |
| M Campone, JM Rademaker-Lakhai, J Bennouna, et al (2005) A Phase I and Pharmacokinetic (PK) Trial of AP5346, a Novel Polymer-Linked DACH Platinum (Pt) Compound, Administered as an Intravenous (IV) Infusion Once a Week for 3 Consecutive Weeks in Advanced Solid Tumor Patients. Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on November 14 - 18 2005 in Philadelphia, PA | Poster |
MuGardTM
| CM Baud, LE Colon, J Gerberich, DP Nowotnik, SB Howell (2006) Protection from Radiation-Induced Oral Mucositis by MuGardTM Oral Rinse A Clinical Study and in silico Analysis. Poster presentation at the 18th International MASCC/ISOO Supportive Care in Cancer Symposium, held on June 22-24 2006 in Toronto, Canada | Poster |
CobalaminTM-Mediated Tumor Targeting
| G Russell-Jones, K McTavish, J McEwan, J Rice, D Nowotnik (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours.J Inorg Biochem. 98, 1625-33. | Abstract |
CobalaminTM-Mediated Oral Drug Delivery
| KB Chalasani, GJ Russell-Jones, et al (2007) A novel vitamin B(12)-nanosphere conjugate carrier system for peroral delivery of insulin, J. Control. Release, 117, 421-429 | Abstract |
| GJ Russell-Jones (2004) Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium, J. Drug Target, 12, 113-123. | Abstract |